IOF Positions and Statements

The newly published clinical practice guidelines from the American College of Physicians (ACP) update the ACP’s 2008 recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women.1 The updated ACP guidelines, simplified to improve access by primary care physicians, emphasize the need for treatment Read more
A new Position Statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated by aromatase-inhibitors (AI) and outlines key management strategies to help prevent bone loss and related fractures. Read more
El documento, publicado conjuntamente por siete organizaciones europeas e internacionales, identifica los factores de riesgo de fractura en pacientes tratados con inhibidores de la aromatasa (IA), y describe las estrategias clave de manejo para ayudar a prevenir la pérdida ósea y fracturas relacionadas. Read more
Although progressive muscle loss is a natural part of ageing, sarcopenia is generally identified when muscle mass and muscle function falls below defined thresholds. Sarcopenia’s impact can be enormous as it affects mobility, balance, risk of falls and fractures, and overall ability to perform tasks of daily living. Given the ageing of populations worldwide, public health and clinical... Read more
Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year. Identifying low adherence to medication – a problem commonly seen with many chronic diseases – is a critical issue as it jeopardizes the efficacy of treatment, leaving... Read more
calcium supplement tablets
An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF) has reviewed the evidence for the value of calcium supplementation, with or without vitamin D supplementation, in healthy musculoskeletal ageing. Read more
A new review by the International Osteoporosis Foundation (IOF) Chronic Inflammation and Bone Structure (CIBS) Working Group concludes that early and aggressive treatment of Rheumatoid Arthritis (RA) with biologic drugs, specifically biological disease-modifying anti-rheumatic drugs (DMARDs), may be most effective in halting progressive bone loss in patients with RA. Read more
Una revisión bibliográfica llevada a cabo por el Grupo de Trabajo sobre Inflamación Crónica y Estructura Ósea (CIBS) de la Fundación Internacional de Osteoporosis (IOF) concluyó que el tratamiento temprano y agresivo de la AR con agentes biológicos, particularmente, aquellos anti-reumáticos que modifiquen biológicamente la enfermedad (DMARDs), podría ser más efectivo para la detención de la... Read more
Below is a Statement issued by IOF to the BMJ in response to: Clinical assessment and management of multimorbidity: summary of NICE guidance. Farmer et al, BMJ 2016; 354: i4843 Read more
Recent research has shown that bone health is compromised in people with diabetes, resulting in a significantly higher risk of fragility fracture. Read more

Pages

Subscribe to IOF Positions and Statements